Second-Line Mesothelioma Treatment: When First-Line Stops Working, What Comes Next

The hardest conversation in mesothelioma care is rarely the one at diagnosis. It is the one that comes a year or eighteen months later, when a CT scan shows the disease moving again and the first-line regimen is no longer doing what it was supposed to do. The options are narrower than at diagnosis, the trial evidence is thinner, and the decision often turns on whether a clinical trial is feasible.

This guide is for people who have just had that conversation, or who are about to. It draws on the phase 3 and phase 2 trial record (CONFIRM, RAMES, NIBIT-MESO-1, IND.227), the NCI Mesothelioma Treatment (PDQ), the ASCO Clinical Practice Guideline, and modified RECIST. The point is to help readers understand the structure of the 2L decision: what the words mean, what the trial data show, and what to ask the oncology team. For background on the standard-of-care landscape that defines first-line therapy, see MesoWatch’s treatment hub.

What “Progression” Actually Means

Before any 2L decision happens, a radiologist has used the word progression on a CT report. That word has a specific clinical meaning in mesothelioma trials.

Standard RECIST 1.1 was designed for tumors that grow as discrete masses. Pleural mesothelioma does not. It grows as a rind around the lung, which makes a single-diameter measurement uninformative. Byrne and Nowak proposed modified RECIST (mRECIST) in Annals of Oncology in 2004 to address this. In mRECIST, radiologists measure pleural tumor thickness perpendicular to the chest wall at multiple defined sites, sum the measurements, and track the sum across scans. Progression is defined as a 20% increase in summed thickness over the lowest prior measurement (the nadir), with a minimum 5 mm absolute increase, or new disease such as a new contralateral pleural effusion.

A single new effusion or a small change in pleural rind thickness can satisfy the progression definition without producing dramatic symptom change. People sometimes feel relatively well at the moment of radiographic progression. The decision to pivot is driven by the imaging trend and the clinical trajectory together, not by one number on one scan.

The Standard Second-Line Options

What counts as a “standard” 2L regimen in mesothelioma is genuinely contested. The 2018 ASCO guideline (Kindler et al., Journal of Clinical Oncology) and its 2022 update both note the absence of a strong-evidence single 2L standard and recommend clinical trial enrollment as the preferred subsequent-line option when feasible. Two trials anchor the evidence base most often referenced in clinic.

CONFIRM (Fennell et al., Lancet Oncology 2021). Phase 3, double-blind, placebo-controlled, 332 patients with relapsed mesothelioma after at least one prior line of platinum-pemetrexed, randomized 2 to 1 to nivolumab or placebo. Median overall survival was 10.2 months with nivolumab versus 6.9 months with placebo (HR 0.72; 95% CI 0.55 to 0.94). Progression-free survival also favored nivolumab. PD-L1 expression did not significantly predict treatment effect. CONFIRM is the largest randomized 2L immunotherapy trial in mesothelioma to date, and MesoWatch covered the biomarker analysis in detail.

RAMES (Pinto et al., Lancet Oncology 2021). Randomized double-blind phase 2 trial of gemcitabine plus ramucirumab (a VEGFR2 antibody) versus gemcitabine plus placebo in 161 patients with progressing pleural mesothelioma. Median overall survival was 13.8 vs 7.5 months (HR 0.71; 70% CI 0.59 to 0.85; p=0.028). The combination is not FDA-approved for this indication.

The NCI Mesothelioma Treatment (PDQ) Health Professional version reflects this state of evidence: it identifies single-agent chemotherapy, checkpoint inhibitor therapy (specifically nivolumab), and clinical trial enrollment as the relevant options, and does not designate any single regimen as the standard.

The picture is also shifting because of what came earlier. Following the FDA’s October 2020 approval of nivolumab plus ipilimumab first-line and the 2023 IND.227/KEYNOTE-483 readout adding pembrolizumab to platinum-pemetrexed, “second-line” increasingly means progression after immunotherapy. Most published 2L immunotherapy data, including CONFIRM, enrolled immunotherapy-naive patients. Whether nivolumab works after first-line nivolumab plus ipilimumab is a different and largely open question.

Investigational Second-Line: What’s in Trials

When the standard 2L options are limited and performance status is good, the next conversation is about clinical trials. Two areas of active investigation come up most often.

TEAD inhibitors. TEAD transcription factors are downstream effectors of the Hippo pathway. Mesothelioma is enriched for inactivating NF2 and LATS2 mutations, making the pathway a credible target. VT-3989, a TEAD palmitoyl-pocket inhibitor, is in a first-in-human phase 1 study (NCT04665206) in NF2-altered solid tumors including pleural mesothelioma. MesoWatch’s VT-3989 coverage summarizes what has been reported.

BAP1-directed approaches. Somatic or germline BAP1 alterations are present in roughly two-thirds of mesotheliomas per Carbone and colleagues. BAP1 loss has been linked to dependence on EZH2, which has motivated trials of EZH2 inhibitors such as tazemetostat in BAP1-deficient disease. We cover the BAP1 mechanistic landscape separately. The relevance for the 2L decision is that BAP1 status, if known, may identify patients eligible for targeted-therapy trials.

Other 2L investigational categories include CAR-T mesothelin-targeted therapy, antibody-drug conjugates, and checkpoint inhibitor combinations with anti-angiogenic agents. The relevant question is not which investigational agent is “best” in the abstract, but which open trial fits the patient’s histology, prior therapy, performance status, and geography.

The Decision: Trial vs Standard 2L vs Best Supportive Care

For most patients with progression and reasonable performance status, the 2L decision sorts into three lanes.

Clinical trial enrollment

ASCO and NCI both flag this as preferred when feasible. A trial places the participant on a structured regimen with active monitoring, often with access to agents not otherwise available. Trials have eligibility criteria that exclude many people (prior therapies that conflict, organ function thresholds, geographic distance), and the participant may end up on the standard-of-care control arm rather than the investigational arm. MesoWatch’s clinical trial enrollment guide, ClinicalTrials.gov, and the Mesothelioma Applied Research Foundation trial finder are starting points.

Standard 2L systemic therapy off-trial

Most often this means single-agent nivolumab (CONFIRM-anchored), or single-agent gemcitabine or vinorelbine. Gemcitabine plus ramucirumab off-label is sometimes considered based on RAMES, but the combination does not have a 2L mesothelioma indication.

Best supportive care alone

For people with deteriorating performance status, significant comorbidity, or progression on multiple prior lines, additional systemic therapy may not extend survival meaningfully and may impose toxicity that erodes quality of life. Palliative care is not a separate track from active treatment; major mesothelioma programs integrate it from the start, and intensifying its role is part of the 2L conversation when the trade-offs change.

The decision among these three is not always sequential or one-time. A patient may enroll in a trial, come off for toxicity or progression, and face the same decision again with different inputs.

Histology and Prior-Therapy Considerations

Two patient-level factors weigh on what 2L options are likely to help.

Histology

Epithelioid mesothelioma generally responds better to platinum-pemetrexed than non-epithelioid (sarcomatoid or biphasic) disease, while the non-epithelioid subgroup historically benefits more from immunotherapy in the CheckMate-743 dataset. CONFIRM showed nivolumab benefit across histology subgroups, but absolute survival numbers and eligibility for investigational trials still vary by histology. People should know their histology and confirm it on the pathology report before the 2L decision is finalized.

Prior therapy

The most consequential 2L distinction is whether the person received first-line immunotherapy. Someone who received platinum-pemetrexed first and is immunotherapy-naive has the strongest evidence base for nivolumab in 2L, anchored by CONFIRM. Someone who progressed on first-line nivolumab plus ipilimumab is in a different position. No large randomized 2L trial covers that population, and the conversation shifts toward chemotherapy (platinum-pemetrexed if not previously given, or single-agent gemcitabine or vinorelbine) and clinical trials. Time on prior therapy matters too: someone who progressed within a few months of starting first-line therapy is in a different prognostic group than someone who progressed after a year or more of disease control.

Practical Questions for the Oncology Team

• What is the mRECIST or RECIST read on the latest scan? The actual measurement change, not “the scan is worse.”
• What is my histology, and was BAP1 or NF2 status assessed?
• Am I eligible for any open clinical trials at this center or a referral center within reasonable travel distance?
• What is your standard 2L recommendation off-trial, and why that one? Single-agent nivolumab, gemcitabine, vinorelbine, and gemcitabine plus ramucirumab are the most common candidates.
• What did published 2L trials show for someone in my situation? CONFIRM (10.2 vs 6.9 months) and RAMES (13.8 vs 7.5 months) are anchor figures.
• What toxicities should we expect, and what is the monitoring plan?
• What are the criteria for stopping treatment if it is not working?
• Is palliative care involved already, and how is it being integrated?

What the Evidence Supports, and What It Does Not

The honest summary of 2L mesothelioma in 2026 is that there is an evidence base, it is useful, and it is not large. CONFIRM, RAMES, and NIBIT-MESO-1 each contribute meaningful signals. None of them, individually or together, defines a single standard regimen the way platinum-pemetrexed defined first-line for two decades.

What the evidence supports: a meaningful subset of patients derives a survival benefit from nivolumab in the 2L setting; gemcitabine-based combinations remain a relevant chemotherapy backbone; clinical trials are the preferred path when feasible; and performance status and prior therapy shape what is reasonable.

What the evidence does not support: that any single 2L regimen is appropriate for all patients regardless of context; that a specific investigational agent is going to “save” a particular patient; or that the absence of a strong-evidence standard means there is nothing useful to do. There is. The work is in matching the option to the patient.

This article was reviewed by Dr. Raffit Hassan, Senior Investigator at the National Cancer Institute, whose work on mesothelin-targeted therapy and immunotherapy combinations informs the 2L landscape described here.

Frequently Asked Questions